ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
PDIA6-SCD1 Axis Rewires Lipid Metabolism to Drive Gastric Cancer Progression.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Gastric cancer (GC) remains an aggressive malignancy with limited effective therapeutic options. Integrated single-cell and bulk transcriptomic analyses identify protein disulfide isomerase A6 (PDIA6) as a tumor epithelial-enriched gene associated with advanced tumor‑ node‑metastasis (TNM) stage and unfavorable survival. Multi-omics profiling reveals that PDIA6 drives lipid metabolic reprogramming by sustaining the monounsaturated fatty acid (MUFA)-enriched neutral lipid pools required for lipid droplet homeostasis and redox balance. Mechanistically, PDIA6 directly associates with stearoyl-CoA desaturase 1 (SCD1) through a structure-defined interface centered on Asp44 of SCD1, thereby restricting its ubiquitin-proteasome-mediated degradation and maintaining SCD1-dependent fatty acid desaturation. In vivo, PDIA6 knockdown suppresses tumor growth and liver metastasis, and synergistic SCD1 inhibition (CAY10566) yields efficacy superior to monotherapies. Upstream, tumor-stromal interactions may contribute to PDIA6 upregulation, as cancer-associated fibroblast-derived C-X-C motif chemokine ligand 12 (CXCL12) activated C-X-C chemokine receptor 4 (CXCR4)-dependent signal transducer and activator of transcription 3 (STAT3) signaling in vitro. These findings establish the PDIA6-SCD1 axis as a targetable lipid metabolic dependency in GC and position PDIA6 as a candidate therapeutic vulnerability for precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.